Key Insights

Highlights

Treatment Research

4 treatments under study, led by Rituximab

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Not Yet Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07257055Phase 2Recruiting

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

NCT07498920Not Yet Recruiting

Gut Microbiome in DLBCL Treated With Glofitamab

Showing all 2 trials

Research Network

Common Treatments

  • Rituximab1
  • Acalabrutinib1
  • Gut Microbiome Analysis1
  • Glofitamab1

Active Sponsors

  • M.D. Anderson Cancer Center1
  • Peking Union Medical College Hospital1

Top Investigators

Related Conditions

  • Gut Biome1
  • Mcl1
  • Btki1
  • Phase 2 Study1
  • Rituximab1

Activity Timeline